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OBJECTIVES: This study aimed to develop a questionnaire to
compare caregiver preferences and satisfaction for oral versus
patch treatment for patients with Alzheimer’s disease (AD).
METHODS: Twenty-three published articles in Medline and the
Patient-Reported Outcome and Quality of Life Instruments
Database (PROQOLID) were identiﬁed and reviewed to aid the
development of an interview guide and draft questionnaire.
Results from caregiver focus groups and clinician interviews in
the US were analyzed, followed by face and content validity
testing to assess the comprehensibility and relevance of the
instrument. RESULTS: From the literary review, 22 domains
were identiﬁed as measures of caregiver satisfaction, including
those related to efﬁcacy, tolerability, and ease of use. The focus
groups consisted of 24 AD caregivers who had been providing
care for an average of four years across a range of disease stages
(25% mild, 58% moderate, 17% severe). Six key challenges
regarding medication limitations, nine major categories of
caregiver-perceived advantages, and nine categories of disadvan-
tages were identiﬁed. The six clinicians interviewed, equally rep-
resenting three medical specialities (psychiatry, geriatrics,
neurology), reacted positively to the initial draft of the question-
naire. Content validity testing in 10 caregivers resulted in a
reduction of answer choices and minor changes to order, struc-
ture, and language to improve clarity and ﬂow. The resultant
Alzheimer’s Disease Caregiver Preference Questionnaire
(ADCPQ) consisted of three modules: module one (baseline)
containing 11 items assessing treatment expectations; module
two (8-week) containing 33 items on the treatment options; and
module three (24-week), containing 10 items assessing treatment
opinions throughout the trial. CONCLUSION: The ADCPQ
may prove a useful research tool to better understand caregiver
preferences for medication regimens and develop improved treat-
ment algorithms for AD. It has already been used in one large,
clinical study (n > 1000), and a blinded in-trial validation is
underway to further reﬁne the questionnaire.
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OBJECTIVES: The objective of this study is to quantify quality-
adjusted disease-progression proﬁles based on the willingness of
older Americans to accept treatment-related risk of death or
permanent severe disability in exchange for modifying the
course of Alzheimer’s disease (AD). AD is a progressive, fatal
condition whose incidence is rising. Little is known about how
the general public views the seriousness of the disease and what
tradeoffs they would accept to modify its course. Data on hypo-
thetical, but clinically relevant treatment tradeoffs can be used
to construct quality-adjusted measures of disease-progression
proﬁles. METHODS: A representative sample of U.S. residents
aged 60 years and older completed an online survey that
included a series of stated-choice trade-off tasks. Subjects chose
between 10 pairs of hypothetical treatment alternatives, each
including different 7-year AD disease-progression proﬁles and
risks related to adverse events that would result in death or
permanent severe disability. We used mixed-logit methods to
estimate healthy-year equivalents for several clinically relevant
disease-progression proﬁles. RESULTS: A total of 2146 subjects
completed the survey. Using the mixed-logit estimates from the
risk-beneﬁt trade-off preferences, a typical 7-year disease pro-
gression of 3 years mild AD (u = 0.73), 2 years moderate AD
(u = 0.53), and 2 years severe AD (u = 0.28) has a mean
healthy-year equivalence of 4.39 years. Using the same assump-
tion above and assuming a utility for permanent severe disabil-
ity of 0.32, a treatment with risks related to adverse events that
prevents AD from progressing beyond the mild stage (7 years of
mild AD) has a mean healthy-year equivalence of 5.71 years.
CONCLUSION: Older Americans’ risk-beneﬁt trade-off prefer-
ences indicate they regard AD as a very serious condition and
that therapies, which could delay worsening from mild AD to
moderate and severe stages could yield increases in healthy-year
equivalents.
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OBJECTIVES: Compare how changes in the medication posses-
sion ratio (MPR) affect patient outcomes among multiple sclero-
sis (MS) patients treated with glatiramer acetate (Copaxone®).
METHODS: Data were obtained from i3’s Lab Rx Database
from September 2001 to June 2006. Patients were included if
they were diagnosed with MS, initiated therapy with Copaxone
and had continuous insurance coverage from 6 months prior
through 24 months post initial use of Copaxone (N = 872).
Multivariate regressions examined the association between use of
achievement of alternative MPR goals and two-year total direct
medical costs or relapse, where relapse was deﬁned as being
hospitalized with a diagnosis of MS or an outpatient visits with
a diagnosis of MS followed by a prescription for steroids within
a seven day period. Regressions also controlled for difference in
patient characteristics. RESULTS: Among patients who initiated
therapy on Copaxone, increases in the MPR were associated with
signiﬁcantly lower odds of relapse. Speciﬁcally, patients who
achieved an MPR of at least 0.7, 0.8 or 0.9 had odds ratio of
relapse of 0.583, 0.530, and 0.437, respectively (P < 0.05). Fur-
thermore, while the use of medications to treat MS (e.g. Copax-
one) resulted in signiﬁcantly higher total direct medical costs, the
marginal impact of medication use on total direct medical costs
decreased as MPR increased. For example, patient with an
MPR0.5 increased costs of $22, 288 (P < 0.0001), while those
with an MPR0.9 had increased costs of $11,707 (P < 0.0001).
CONCLUSION: Increases in the MPR for Copaxone is associ-
ated with a reduction in patient’s marginal cost of medical treat-
ment. This result suggest that, despite the higher costs associated
with increased usage of Copaxone, there are costs offsets asso-
ciated with “compliant” use of the medication. Furthermore,
results from this study indicate that a higher MPR for Copaxone
is associated with signiﬁcant reductions the probability of
relapse.
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